Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 192

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer

Open access
Bosco, Emily E., Wang, Ying, Xu, Huan, Zilfou, Jack T., Knudsen, Karen E., Aronow, Bruce J., Lowe, Scott W., Knudsen, Erik S.·2007·Journal of Clinical Investigation

Abstract

The retinoblastoma tumor suppressor (RB) protein is functionally inactivated in the majority of human cancers and is aberrant in one-third of all breast cancers. RB regulates G(1)/S-phase cell-cycle progression and is a critical mediator of antiproliferative signaling. Here the specific impact of RB deficiency on E2F-regulated gene expression, tumorigenic proliferation, and the response to 2 distinct lines of therapy was investigated in breast cancer cells. RB knockdown resulted in RB/E2F target gene deregulation and accelerated tumorigenic proliferation, thereby demonstrating that even in the context of a complex tumor cell genome, RB status exerts significant control over proliferation. Furthermore, the RB deficiency compromised the short-term cell-cycle inhibition following cisplatin, ionizing radiation, and antiestrogen therapy. In the context of DNA-damaging agents, this bypass resulted in increased sensitivity to these agents in cell culture and xenograft models. In contrast, the bypass of antiestrogen signaling resulted in continued proliferation and xenograft tumor growth in the presence of tamoxifen. These effects of aberrations in RB function were recapitulated by ectopic E2F expression, indicating that control of downstream target genes was an important determinant of the observed responses. Specific analyses of an RB gene expression signature in 60 human patients indicated that deregulation of this pathway was associated with early recurrence following tamoxifen monotherapy. Thus, because the RB pathway is a critical determinant of tumorigenic proliferation and differential therapeutic response, it may represent a critical basis for directing therapy in the treatment of breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci28803

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 192

Metadata

Authors
Bosco, E. E., Wang, Y., Xu, H., Zilfou, J. T., Knudsen, K. E., Aronow, B. J., Lowe, S. W., & Knudsen, E. S.
Venue
Journal of Clinical Investigation
Published
2007-01-02
Volume
117
Issue
1
Pages
218-228
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2159058669
Cited by
192
References
4
FWCI
5.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. https://app.cochat.ai/papers/10.1172/jci28803
The paper
Bosco, E. E., Wang, Y., Xu, H., Zilfou, J. T., Knudsen, K. E., Aronow, B. J., Lowe, S. W., & Knudsen, E. S. (2007). The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci28803

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.